Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← KRAS / RAS targeting: from platform to Phase 3

MEK

Clinical trial

3 people · 3 posts · 1 abstract

Heat trend for this story

Heat now 1·Peak in the comparable set 1 (Apr 21 03:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1
00.250.50.751
Heat over time
00.250.50.751Apr21Apr21Apr21Apr21

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

Other cases in this chapter
  • daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
  • daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
  • zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
  • VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
  • elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
  • RM-055Active in daraxonrasib-resistant and RAS-amplification models
Evidence
CT129
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

Read the abstract →
Floor
Apr 21Tue
Apr 20Mon
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org